Patent US3984545A successfully refreshed from Google Patents.
US3984545A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel method and compositions for treating paralysis agitans
Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-08-06
•
Granted: 1976-10-05
•
Expires: 1995-08-06
Abstract
Abstract An improvement in the method of treating paralysis agitans by administration of 3,4-dihydroxy-phenyl-1-alanine, its hydrates and salts thereof is disclosed, which comprises administering it concurrently with a benzodiazepine compound having sedative-hypnotic and anxiolytic activity. Disclosed also are therapeutic compositions which comprise mixtures of 3,4-dihydroxyphenyl-1-alanine with benzodiazepines. The therapeutic compositions are useful in the treatment of humans afflicted with paralysis agitans.
Inventors
- 👤 Walter Frils, Jr.
- 👤 Allan D. Rudzik
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 09:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
137 words
A method of treatment of paralysis agitans comprising administering from about 250 mg. to about 500 mg. of a compound selected from the group consisting of 3,4-dihydroxyphenyl-1-alanine, a hydrate thereof, or a pharmaceutically acceptable acid addition salt thereof and the coadministering of a potentiating dose of a member selected from the group consisting of 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide and a compound of the formula: ##SPC6## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, and lower alkanoyl; R 2 is selected from the group consisting of hydrogen and lower alkyl; and R 3 , R 4 , and R 5 are each selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, amino, lower-alkanoylamino, lower-alkylthio, lower-alkylsulfonyl, lower-alkylsulfinyl, lower-alkoxy, hydroxy, lower alkyl, cyano, carboxy and di-lower alkylamino.
Claim 2
Independent Claim
137 words
A method of treatment of paralysis agitans comprising administering from about 250 mg. to about 500 mg. of a compound selected from the group consisting of 3,4-dihydroxyphenyl-1-alanine, a hydrate thereof, or a pharmaceutically acceptable acid addition salt thereof and the coadministering of a potentiating dose of a member selected from the group consisting of 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide and a compound of the formula: ##SPC6## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, and lower alkanoyl; R 2 is selected from the group consisting of hydrogen and lower alkyl; and R 3 , R 4 , and R 5 are each selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, amino, lower-alkanoylamino, lower-alkylthio, lower-alkylsulfonyl, lower-alkylsulfinyl, lower-alkoxy, hydroxy, lower alkyl, cyano, carboxy and di-lower alkylamino.
Claim 3
Dependent Claim
139 words
A unit dose pharmaceutical composition which consists essentially of from about 250 mg. to about 500 mg. of a compound selected from the group consisting of 3,4-dihydroxyphenyl-1-alanine, a hydrate thereof, or a pharmaceutically acceptable acid addition salt thereof and from about 1 mg. to about 5 mg. of a member selected from the group consisting of 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide and a compound of the formula: ##SPC7## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, and lower alkanoyl; R 2 is selected from the group consisting of hydrogen and lower alkyl; and R 3 , R 4 , and R 5 are each selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, amino, lower-alkanoylamino, lower-alkylthio, lower-alkylsulfonyl, lower-alkylsulfinyl, lower-alkoxy, hydroxy, lower alkyl, cyano, carboxy and di-lower alkylamino.
Claim 4
Dependent Claim
139 words
A unit dose pharmaceutical composition which consists essentially of from about 250 mg. to about 500 mg. of a compound selected from the group consisting of 3,4-dihydroxyphenyl-1-alanine, a hydrate thereof, or a pharmaceutically acceptable acid addition salt thereof and from about 1 mg. to about 5 mg. of a member selected from the group consisting of 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide and a compound of the formula: ##SPC7## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, and lower alkanoyl; R 2 is selected from the group consisting of hydrogen and lower alkyl; and R 3 , R 4 , and R 5 are each selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, amino, lower-alkanoylamino, lower-alkylthio, lower-alkylsulfonyl, lower-alkylsulfinyl, lower-alkoxy, hydroxy, lower alkyl, cyano, carboxy and di-lower alkylamino.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-10-05 | 1980-04-05 | 1980-10-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-10-05 | 1984-04-05 | 1984-10-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-10-05 | 1988-04-05 | 1988-10-05 | $7700.00 | Window Closed / Lapsed |